- Home
- EIM vs FDMT Comparison
EIM vs FDMT Comparison
Compare EIM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIM | FDMT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.2M | 513.6M |
| IPO Year | 2002 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EIM | FDMT |
|---|---|---|
| Price | $9.99 | $8.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $34.13 |
| AVG Volume (30 Days) | 165.6K | ★ 753.7K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,000.00 |
| Revenue This Year | N/A | $21,227.03 |
| Revenue Next Year | N/A | $161.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.27 | $2.24 |
| 52 Week High | $10.54 | $12.34 |
Technical Indicators
Market Signals| Indicator | EIM | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 43.30 |
| Support Level | $9.83 | $8.11 |
| Resistance Level | $10.04 | $8.80 |
| Average True Range (ATR) | 0.04 | 0.57 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 52.17 | 14.85 |
Price Performance
Historical ComparisonAbout EIM Eaton Vance Municipal Bond
Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.